A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

Array BioPharma Inc.0 sites160 target enrollmentStarted: April 17, 2018Last updated: June 22, 2020

Trial Snapshot

Phase: Phase 1
Status: Active, not recruiting
Sponsor: Array BioPharma Inc.
Enrollment: 160

Study Overview Eligibility Criteria Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Interventional clinical trial of medicinal product

Eligibility Criteria

Sex: All

Inclusion Criteria

•Selected Key Inclusion Criteria:
•Provide a signed and dated informed consent document prior to
•initiation of any study-related procedures. Patients under guardianship
•or partial guardianship will be eligible unless prohibited by local laws or
•by local/central ethic committees
•Age = 18 years at time of informed consent
•Patients with symptomatic lamin A/C protein (LMNA)-related cardiomyopathy Class II/III/ or Class IV defined as:
•o Gene positive for a deleterious mutation in the LMNA gene as
•determined by the study central laboratory or by initial laboratory
•testing (central confirmation of initial laboratory results is required prior
•to randomization
•o Evidence of cardiac impairment as determined by EF = 50%
•Patient will have an implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator (ICD/CRT-D). ICD implanted at least 4 weeks prior to initiation of study treatment or CRT-D initiated at least 6 months prior to initiation of study treatment. Devices must include pacing capabilities or a separate pacemaker must be present.
•Class II/III patients must have objective functional impairment evidenced by a reduction in 6-minute walk test (6MWT);
•Stable medical and/or device therapy consistent with American Heart Association (AHA) / American College of Cardiology (ACC) or European Society of Cardiology (ESC) guidelines
•Patients must meet acceptable hematology, hepatic and renal laboratory values as specified within 35 days prior Day 1
•Affiliated to a social security system, or is a beneficiary (if applicable in
•the national regulation)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 140
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

•Selected Key Exclusion Criteria:
•Presence of other form(s) of cardiomyopathy contributing to HF (e.g., inflammatory or infiltrative cardiomyopathy) or clinically significant cardiac anatomic abnormality (e.g., LV aneurysm).
•Clinically significant coronary artery disease (e.g., coronary revascularization, exercise-induced angina) per Investigator judgment.
•Uncorrected, hemodynamically significant (i.e., moderatesevere) primary structural valvular disease not due to HF.
•Currently receiving or deemed at high risk of requiring chronic renal replacement therapy (e.g., hemodialysis or peritoneal dialysis) within 6 months.
•Treatment with any investigational agent(s) for HF within 35 days prior to Day 1. Any treatment with an investigational agent(s) requires approval from the Medical Monitor.
•Malignancy that is active or has been diagnosed within 3 years prior to screening, except surgically curatively resected in situ malignancies or surgically cured early breast cancer, prostate cancer, skin cancer (basal cell carcinoma, squamous cell carcinoma), thyroid cancer or cervical
•cancer, or, with prior approval from the Medical Monitor, other early stage surgically curatively resected malignancies with less than a 20% expected 2-year recurrence rate.
•Non-cardiac condition that limits lifespan to < 1 year.
•Serum positive for hepatitis B surface antigen, viremic hepatitis C, or human immunodeficiency virus (HIV) at screening.
•Pregnancy or breastfeeding, or patients who plan to become pregnant
•during the duration of the trial
•Patients with an underlying condition that may impact the ability of the
•6MWT to reflect changes in cardiovascular function such as: an
•orthopedic condition that limits walking abilities (e.g., severe arthritis),
•significant musculoskeletal pathology, significant chronic obstructive
•pulmonary disease (COPD) that limits exercise tolerance or any other
•condition that according to the Investigator's assessment significantly
•limits a patient's performance on the 6MWT independently from the
•patient's cardiomyopathy.
•Documented hypersensitivity/allergy or clinically significant
•intolerance to any component of drug product.

Investigators

Sponsor

Array BioPharma Inc.

Similar Trials

Active, not recruiting

Phase 1

A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene MutatioDilated Cardiomyopathy (DCM) with Lamin A/C gene (LMNA) MutationMedDRA version: 20.0Level: LLTClassification code 10056419Term: Dilated cardiomyopathySystem Organ Class: 100000004849

EUCTR2017-004310-25-BEArray BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)160

Active, not recruiting

Phase 1

A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutatio

EUCTR2017-004310-25-NLArray BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)160

Active, not recruiting

Phase 1

EUCTR2017-004310-25-NOArray BioPharma Inc.160

Active, not recruiting

Phase 1

A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene MutatioDilated Cardiomyopathy (DCM) with Lamin A/C protein (LMNA) MutationMedDRA version: 20.0Level: LLTClassification code 10056419Term: Dilated cardiomyopathySystem Organ Class: 100000004849

EUCTR2017-004310-25-ITARRAY BIOPHARMA INC.160

Active, not recruiting

Phase 1

EUCTR2017-004310-25-DKArray BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)200